Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer ; volume:18 ; number:5 ; day:16 ; month:9 ; year:2023 ; pages:801 ; date:9.2023
Targeted oncology ; 18, Heft 5 (16.9.2023), 801, 9.2023
- Creator
-
Lee, Arnold
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-023-01003-2
- URN
-
urn:nbn:de:101:1-2023121213132843420715
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Arnold
- SpringerLink (Online service)
Other Objects (12)
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review